Schizophrenia Clinical Trial
Official title:
A Phase I, Open Label, Single Center, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetic Profile of RBP-7000 at Low, Medium, and High Doses
Verified date | May 2016 |
Source | Indivior Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
The purpose of this study was to assess the safety and tolerability of injections of RBP-7000 in subjects with stable schizophrenia
Status | Completed |
Enrollment | 45 |
Est. completion date | February 2012 |
Est. primary completion date | February 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Subjects with confirmed diagnosis of paranoid, residual, or undifferentiated schizophrenia in a documented letter from the subject's psychiatrist or primary care provider. - Clinically stable subjects (subjects whom the PI established by medical record or by history from the subject and at least 1 reliable informant, that the subject had been clinically stable for at least 60 days without hospitalization). - Subjects with body mass index (BMI) between 18 and 33 kg/m2 and weight of at least 49.9 kg. - Subjects who gave written informed consent. Exclusion Criteria: - Subjects taking any risperidone product within the last 60 days prior to study screening. - Subjects with a history of cancer (excluding resected basal cell or squamous cell carcinoma of the skin) unless they had been disease free for = 5 years. - Subjects with another active medical condition or organ disease that could have either compromised subject safety or interfered with the safety and/or outcome evaluation of the study drug. This included, but was not limited to the following abnormalities: total bilirubin > 2.5 mg/dL (51 µmol/L), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 × the upper limit of normal (ULN) or clinically significant serum creatinine > 2 x ULN, international normalized ratio (INR) = 2.0. Other excluded medical conditions included, but were not limited to: history of heart attack, brain injury, low blood pressure, and clinically significant irregular heartbeat as interpreted by the PI. - Subjects who were known to have acquired immune deficiency syndrome or to be human immunodeficiency virus (HIV) positive. - Subjects with evidence or history of significant hepatic disorder, including acute or chronic hepatitis B and acute hepatitis C. Subjects with hepatitis C antibody and liver functions = 1.5 times the ULN could be included in the study. - Subjects with known diagnosis of type 1 or 2 diabetes or subjects with a clinically significant abnormal hemoglobin A1c (HbA1c) at screening as interpreted by the PI. - Subjects with clinically significant comorbidities that could affect near-term survival. - Subjects treated with any investigational drug within the last 30 days prior to study screening. - Subjects with significant traumatic injury, major surgery, or open biopsy within the last 4 weeks prior to study screening. - Subjects receiving opioid or opioid-containing analgesics within the last 30 days prior to study screening. - Subjects consuming > 1 alcoholic drink per day within the last 30 days prior to study screening (defined as 1 oz. of 80 proof spirits, 12 oz. of beer, or 4 oz. of wine). - Subjects with prior allergic reactions, sensitivities, or other known contraindications to any component of RBP-7000 (i.e., risperidone, poly [DL-lactide-co-glycolide], or N-methylpyrrolidone). - Subjects with other concurrent uncontrolled illness that may have interfered with the ability to participate in the study. - Women with a positive pregnancy test at screening. Women of childbearing potential, who were pregnant or lactating, seeking pregnancy, or failing to take adequate contraceptive precautions (e.g., an oral or injectable contraceptive, an approved hormonal implant or topical patch, or an intrauterine device). Should a female subject become sexually active, she must have agreed to use a double-barrier method or barrier plus spermicide. A woman of childbearing potential was defined as any female who was less than 2 years post-menopausal or had not undergone a hysterectomy or surgical sterilization, e.g., bilateral tubal ligation or bilateral ovariectomy (oophorectomy). Females who were post-menopausal were confirmed by the follicle stimulating hormone (FSH) test at initial screening. - Subjects with a positive urine drug screen for opioids, cocaine, amphetamines, methadone, marijuana, barbiturates, benzodiazepines, methamphetamine, phencyclidine, or tricyclic antidepressants unless the positive screen was determined to be secondary to an allowable concomitant medication. - Subjects with epilepsy or other seizure disorders, Parkinson's disease, or dementia. - Subjects taking bupropion, chlorpheniramine, cimetidine, clomipramine, doxepin, or quinidine within the last 30 days prior to study screening. - Subjects taking clozapine, phenothiazines, aripiprazole, or haloperidol within the last 30 days prior to study screening. - Subjects taking serotonin reuptake inhibitors (e.g., fluoxetine, paroxetine) within the last 30 days prior to study screening. - Subjects taking medications, in addition to those listed above, which may have been expected to significantly interfere with the metabolism or excretion of risperidone and/or 9-hydroxyrisperidone that may have been associated with a significant drug interaction with risperidone, or may have posed a significant risk to subjects' participation in the study. - Subjects who had been previously injected with RBP-7000 in this study. Subjects who were unable, in the opinion of the PI, to comply fully with the study requirements. |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | CRI Worldwide | Willingboro | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Indivior Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] after a subcutaneous injection of a single 60 mg, 90 mg, and 120 mg dose of risperidone in RBP-7000 in subjects with clinically stable schizophrenia | Adverse events, serious adverse events, and discontinuations due to AEs related to treatment. | Day 1 through Day 85 | Yes |
Secondary | Maximum plasma concentration (Cmax) of risperidone and total risperidone | Blood samples for PK were collected and analyzed for concentration data of risperidone, 9-hydroxyrisperidone, and total risperidone throughout the study period | Day 0 through Day 85 | No |
Secondary | Time of occurrence of Cmax (Tmax) of risperidone and total risperidone | Blood samples for PK were collected and analyzed for concentration-time data of risperidone, 9-hydroxyrisperidone, and total risperidone throughout the study period | Day 0 through time of last quantifiable concentration | No |
Secondary | Area under the plasma concentration versus time curve (AUC) | Area under the risperidone and total risperidone plasma concentration-time curves from time-zero to Day 85 | Day 0 through Day 85 | No |
Secondary | Observed terminal rate constant of risperidone and total risperidone (?z) | ?z estimated by linear regression through at least 3 data points in the terminal phase of the log concentration-time profile | Day 0 through Day 85 | No |
Secondary | Terminal half-life of risperidone and total risperidone (T1/2) | The observed terminal half-life of risperidone, 9-hydroxyrisperidone, and total risperidone was calculated | Day 0 through Day 85 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |